Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

StockNews.com upgraded shares of Novo Nordisk A/S (NYSE:NVO – Free Report) from a buy rating to a strong-buy rating in a report released on Thursday. A number of other analysts have also recently ...

Market volatility and tech sector sell-offs have dragged Tesla shares (TSLA) lower, erasing post-election gains seen after President Trump's 2024 victory and the stock falling 50% since December.